The impact of multiple sclerosis relapse treatment on migration of effector T cells--Preliminary study.

Autor:	Jatczak-Pawlik I; Department of Propedeutics of Neurology, Medical University of Lodz, Lodz, Poland., Książek-Winiarek D; Department of Propedeutics of Neurology, Medical University of Lodz, Lodz, Poland; Department of Neurology and Stroke, Medical University of Lodz, Lodz, Poland. Electronic address: dominika.ksiazek@umed.lodz.pl., Wojkowska D; Department of Propedeutics of Neurology, Medical University of Lodz, Lodz, Poland; Department of Neurology and Stroke, Medical University of Lodz, Lodz, Poland., Jóźwiak K; Department of Propedeutics of Neurology, Medical University of Lodz, Lodz, Poland; Department of Neurology and Stroke, Medical University of Lodz, Lodz, Poland., Jastrzębski K; Department of Neurology and Stroke, Medical University of Lodz, Lodz, Poland., Pietruczuk M; Department of Laboratory Diagnostics, Medical University of Lodz, Lodz, Poland., Głąbiński A; Department of Propedeutics of Neurology, Medical University of Lodz, Lodz, Poland; Department of Neurology and Stroke, Medical University of Lodz, Lodz, Poland.
Jazyk:	angličtina
Zdroj:	Neurologia i neurochirurgia polska [Neurol Neurochir Pol] 2016; Vol. 50 (3), pp. 155-62. Date of Electronic Publication: 2016 Feb 20.
DOI:	10.1016/j.pjnns.2016.02.003
Abstrakt:	Unlabelled: Migration of inflammatory cells from the blood to the central nervous system (CNS) is crucial for development of multiple sclerosis (MS). Inhibition of this process would allow to control disease activity. The first step confirming this approach would be the analysis of the impact of effective MS relapse therapy on migration of effector T cells. The aim of the study was to analyze the influence of methylprednisolone (MP) on the migratory activity of effector CD4+ T cells from MS patients. Moreover, to study the potential mechanism of this process we studied expression of chemokine receptors on migrating cells. Material and Methods: Peripheral blood samples were obtained from relapsing-remitting MS (RR-MS) patients during relapse (n=23) and from control group (n=23). After isolation CD4+ T cells were incubated with various concentrations of MP. Then they were stimulated in chemotaxis assay with chemokines CCL3 or CXCL10 or were used to CCR1 and CXCR3 expression analysis. Results: CXCL10- and CCL3-stimulated migration of CD4+ T cells was significantly increased in MS. MP was able to reduce in vitro migration of effector T cells induced by CXCL10, but not by CCL3. Inhibition by MP was dose-dependent. Expression of analyzed chemokine receptors was unaltered after MP incubation. Conclusions: MP reduced CD4+ T cells migration induced by CXCL10 without affecting CXCR3 expression. These observations demonstrate one of the potential mechanisms of MP action in MS, distinct from inducing cell apoptosis, and suggests the new targets for development of more effective MS treatments. (Copyright © 2016 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu